The supplied record set links AngioDynamics, Inc. to one 510(k) entry in the sampled filings: K263076 for a device named AngioVac F1885, decided 2026-10-30 as substantially equivalent. The applicant address on that filing is in Queensbury, New York, which is a filing address rather than a verified headquarters. Company-published pages describe the AngioVac System as an on-circuit aspiration option and the AlphaVac System as a separate product line, while a separate FDA decision letter covers an AlphaVac F18 85 System under K252509. [1][2][6]
Documented 510(k) activity
The sampled 510(k) record for AngioDynamics, Inc. is K263076, received 2026-09-01 and decided 2026-10-30 with decision code SESE, described as substantially equivalent. The device name on that record is AngioVac F1885, product code DWF, advisory committee Cardiovascular, clearance type Traditional, and the statement field indicates a Summary. The full supplied collection contains one 510(k) record with one SESE decision, and the explicitly smaller record sample likewise contains one record with one SESE decision; these counts describe the supplied filings only. [1]
A separate FDA decision letter, dated November 24, 2025, addresses K252509 for the AlphaVac Multipurpose Mechanical Aspiration (MMA) F18 85 System, with regulation number cited as 21 CFR 870.5150 and product codes QEZ and KRA. That letter is a distinct document from the sampled 510(k) row and is not part of the supplied portfolio counts. [6]
AngioVac System as published
AngioDynamics' AngioVac product page describes the system as an on-circuit aspiration option that simultaneously reinfuses filtered blood back into the patient, and states that it provides surgical results via percutaneous access while minimizing blood loss. The same page lists cannula variants labeled F1885, F22180 and F2220. These are company-published product descriptions attributed to AngioDynamics. [2]
The AngioVac.com site presents the F18 85 cannula as a longer, smaller cannula paired with the legacy extracorporeal bypass circuit, and describes the F22 cannula family as available with 20-degree and 180-degree angled tips. The site cites a published registry reference for the system; no outcome figures from that reference are reproduced here. [4]
AlphaVac System and portfolio context
The AlphaVac product page on AngioDynamics' site presents the AlphaVac System as a distinct product with its own handle and backend views, and carries a citation to a single-center review of acute limb ischemia. The page does not state clearance dates or indications in the supplied excerpt. [3]
An AngioDynamics investor release dated January 6, 2026 reports the company's fiscal year 2026 second quarter results and lists three regulatory milestones for its mechanical thrombectomy portfolio: a modified AlphaVac 510(k) clearance and PAVE and APEX-Return IDE approvals. The release is the publisher's own account; the underlying clearances and approvals are not reproduced in the public documents beyond the K252509 letter. [7]
Identity and scope limits
Across the public documents, AngioDynamics, Inc. appears as the FDA applicant on K263076 and as the publisher of the AngioVac and AlphaVac product pages. No parent company, brand ownership structure, customer list, or commercial availability outside the cited pages is verified in these sources, and the Queensbury address appears only in filing and letter contexts. [1][2][5]
The risk-information page hosted by AngioDynamics is referenced from the AngioVac product page, but the supplied excerpt contains navigation and contact-form content rather than product-specific risk text. Product availability statements on the company site direct readers to local representatives, indicating regional variation without specifying markets. [2][5]

